References
1. Eriksson J, Ekerljung L, Rönmark E, et al. Update of prevalence of self-reported allergic rhinitis and chronic nasal symptoms among adults in Sweden. The clinical respiratory journal. 2012;6(3):159-168.
2. Warm K, Hedman L, Lindberg A, Lötvall J, Lundback B, Rönmark E. Allergic sensitization is age-dependently associated with rhinitis, but less so with asthma. The Journal of allergy and clinical immunology. 2015;136(6):1559-1565.e1551-1552.
3. Newson RB, van Ree R, Forsberg B, et al. Geographical variation in the prevalence of sensitization to common aeroallergens in adults: the GA(2) LEN survey. Allergy. 2014;69(5):643-651.
4. Cardell LO, Olsson P, Andersson M, et al. TOTALL: high cost of allergic rhinitis-a national Swedish population-based questionnaire study. NPJ primary care respiratory medicine. 2016;26:15082.
5. Di Bona D, Bilancia M, Albanesi M, Caiaffa MF, Macchia L. Cost-effectiveness of grass pollen allergen immunotherapy in adults.Allergy. 2020.
6. Akdis CA, Akdis M. Mechanisms of allergen-specific immunotherapy and immune tolerance to allergens. The World Allergy Organization journal. 2015;8(1):17.
7. Roberts G, Pfaar O, Akdis CA, et al. EAACI Guidelines on Allergen Immunotherapy: Allergic rhinoconjunctivitis. Allergy.2018;73(4):765-798.
8. Klimek L, Pfaar O, Bousquet J, Senti G, Kundig T. Allergen immunotherapy in allergic rhinitis: current use and future trends.Expert review of clinical immunology. 2017;13(9):897-906.
9. Hoffmann HJ, Valovirta E, Pfaar O, et al. Novel approaches and perspectives in allergen immunotherapy. Allergy.2017;72(7):1022-1034.
10. Dhami S, Nurmatov U, Arasi S, et al. Allergen immunotherapy for allergic rhinoconjunctivitis: A systematic review and meta-analysis.Allergy. 2017;72(11):1597-1631.
11. Arvidsson MB, Löwhagen O, Rak S. Effect of 2-year placebo-controlled immunotherapy on airway symptoms and medication in patients with birch pollen allergy. The Journal of allergy and clinical immunology.2002;109(5):777-783.
12. Durham SR, Penagos M. Sublingual or subcutaneous immunotherapy for allergic rhinitis? Journal of Allergy and Clinical Immunology.2016;137(2):339-349.e310.
13. Senti G, Prinz Vavricka BM, Erdmann I, et al. Intralymphatic allergen administration renders specific immunotherapy faster and safer: a randomized controlled trial. Proc Natl Acad Sci U S A.2008;105(46):17908-17912.
14. Patterson AM, Bonny AE, Shiels WE, 2nd, Erwin EA. Three-injection intralymphatic immunotherapy in adolescents and young adults with grass pollen rhinoconjunctivitis. Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology. 2016;116(2):168-170.
15. Schmid JM, Nezam H, Madsen HH, Schmitz A, Hoffmann HJ. Intralymphatic immunotherapy induces allergen specific plasmablasts and increases tolerance to skin prick testing in a pilot study.Clinical and translational allergy. 2016;6:19.
16. Hylander T, Larsson O, Petersson-Westin U, et al. Intralymphatic immunotherapy of pollen-induced rhinoconjunctivitis: a double-blind placebo-controlled trial. Respir Res. 2016;17:10.
17. Hellkvist L, Hjalmarsson E, Kumlien Georen S, et al. Intralymphatic immunotherapy with 2 concomitant allergens, birch and grass: A randomized, double-blind, placebo-controlled trial. The Journal of allergy and clinical immunology. 2018;142(4):1338-1341 e1339.
18. Ahlbeck L, Ahlberg E, Nyström U, Björkander J, Jenmalm MC. Intralymphatic allergen immunotherapy against pollen allergy: A 3-year open follow-up study of 10 patients. Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology. 2018;121(5):626-627.
19. Witten M, Malling HJ, Blom L, Poulsen BC, Poulsen LK. Is intralymphatic immunotherapy ready for clinical use in patients with grass pollen allergy? The Journal of allergy and clinical immunology. 2013;132(5):1248-1252 e1245.
20. Senti G, Freiburghaus AU, Larenas-Linnemann D, et al. Intralymphatic Immunotherapy: Update and Unmet Needs. International archives of allergy and immunology. 2019;178(2):141-149.
21. Devillier P, Chassany O, Vicaut E, et al. The minimally important difference in the Rhinoconjunctivitis Total Symptom Score in grass-pollen-induced allergic rhinoconjunctivitis. Allergy.2014;69(12):1689-1695.
22. Juniper EF, Thompson AK, Ferrie PJ, Roberts JN. Validation of the standardized version of the Rhinoconjunctivitis Quality of Life Questionnaire. The Journal of allergy and clinical immunology.1999;104(2 Pt 1):364-369.
23. Fauquert J-L, Jedrzejczak-Czechowicz M, Rondon C, et al. Conjunctival allergen provocation test : guidelines for daily practice.Allergy. 2017;72(1):43-54.
24. Pfaar O, Agache I, Bergmann K, et al. Placebo effects in allergen immunotherapy – an EAACI Task Force Position Paper.Allergy. n/a(n/a).
25. Freiberger SN, Zehnder M, Gafvelin G, Grönlund H, Kündig TM, Johansen P. IgG4 but no IgG1 antibody production after intralymphatic immunotherapy with recombinant MAT-Feld1 in human. Allergy.2016;71(9):1366-1370.
26. Kowalski ML, Ansotegui I, Aberer W, et al. Risk and safety requirements for diagnostic and therapeutic procedures in allergology: World Allergy Organization Statement. The World Allergy Organization journal. 2016;9(1):33.
27. Schiappoli M, Ridolo E, Senna G, et al. A prospective Italian survey on the safety of subcutaneous immunotherapy for respiratory allergy.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology. 2009;39(10):1569-1574.
28. Aasbjerg K, Dalhoff KP, Backer V. Adverse Events During Immunotherapy Against Grass Pollen-Induced Allergic Rhinitis - Differences Between Subcutaneous and Sublingual Treatment. Basic Clin Pharmacol Toxicol. 2015;117(2):73-84.
29. Bousquet J, Schünemann HJ, Bousquet PJ, et al. How to design and evaluate randomized controlled trials in immunotherapy for allergic rhinitis: an ARIA-GA(2) LEN statement. Allergy.2011;66(6):765-774.
30. Wagenmann M, Worm M, Akboga Y, Karjalainen M, Hohlfeld JM. Randomized immunotherapy trial in dual-allergic patients using ”active allergen placebo” as control. Allergy. 2019;74(8):1480-1489.
31. Jacobsen L, Niggemann B, Dreborg S, et al. Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study. Allergy. 2007;62(8):943-948.
32. Valovirta E, Petersen TH, Piotrowska T, et al. Results from the 5-year SQ grass sublingual immunotherapy tablet asthma prevention (GAP) trial in children with grass pollen allergy. The Journal of allergy and clinical immunology. 2018;141(2):529-538.e513.
33. Pajno GB, Barberio G, De Luca F, Morabito L, Parmiani S. Prevention of new sensitizations in asthmatic children monosensitized to house dust mite by specific immunotherapy. A six-year follow-up study.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology. 2001;31(9):1392-1397.
34. Bender BG, Oppenheimer J. The special challenge of nonadherence with sublingual immunotherapy. The journal of allergy and clinical immunology In practice. 2014;2(2):152-155.
35. Hedenström H, Malmberg P, Fridriksson HV. Reference values for lung function tests in men: regression equations with smoking variables.Upsala journal of medical sciences. 1986;91(3):299-310.
36. Hedenström H, Malmberg P, Agarwal K. Reference values for lung function tests in females. Regression equations with smoking variables.Bulletin europeen de physiopathologie respiratoire.1985;21(6):551-557.
37. Miyara M, Yoshioka Y, Kitoh A, et al. Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor. Immunity. 2009;30(6):899-911.
38. Jenmalm MC, Björksten B, Macaubas C, Holt BJ, Smallacombe TB, Holt PG. Allergen-induced cytokine secretion in relation to atopic symptoms and immunoglobulin E and immunoglobulin G subclass antibody responses.Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology.1999;10(3):168-177.
39. Forsberg A, Abrahamsson TR, Björksten B, Jenmalm MC. Pre- and post-natal Lactobacillus reuteri supplementation decreases allergen responsiveness in infancy. Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.2013;43(4):434-442.
TABLE 1 Baseline characteristics by treatment group, presented as mean and standard deviation